Supervisory Board's opinion on the recommendation of the Company's Management Board regarding the allocation of 2025 profit

Date: 20 April 2026

Subject: Supervisory Board’s opinion on the recommendation of the Company’s Management Board regarding the allocation of 2025 profit

Legal basis: Article 17(1) of MAR – Inside information

Text of the report:

Further to Current Report No. 2/2026 of 20 April 2026 on the recommendation of the Management Board of Diagnostyka S.A. (the “Company”) regarding the allocation of profit for 2025, the Management Board announces that the Supervisory Board, at its meeting held on 20 April 2026, endorsed the Management Board’s recommendation of the following allocation of the Company’s 2025 profit of PLN 233,111,757.67:

• PLN 148,528,600.00 to be distributed as dividend of PLN 4.40 per share;
• the balance of PLN 84,585,157.67 to be transferred to the Company’s statutory reserve funds.

The dividend payout ratio is 59.04% of the amount disclosed in the Group’s financial statements under net profit attributable to owners of the parent.

The Company’s governing body competent to resolve on the allocation of profit, including dividend payment, is the General Meeting.

Specific legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/82/EC (OJ L 173) (“MAR”).

For the Company:

Dariusz Zowczak – Vice President of the Management Board

Marta Rogalska-Kupiec – Vice President of the Management Board